The Patterson Analysis

Montreal's Salutt Inc. launches Ready to Date, betting its 'Love Compass' can fix a broken dating scene. But can it overcome the user density paradox?

While 30,000 union hotel workers celebrate a landmark contract, staff at two Times Square hotels picket for a living wage, backed by the city's top brass.

As BNL preps its Q2 report, its industrial pivot and build-to-suit success face a tough macroeconomic climate. We analyze the key metrics beyond the headlines.

General Motors' H1 2026 sales crown isn't just a headline. It's a case study in a dual-engine strategy that perfectly meets the Canadian market where it is.

The recent funding for Luxonis isn't just another AI investment. It’s a validation of edge computing, where intelligent machines see and act in the real world.

West's $112.5M sale of its 3.5mL device to AbbVie isn't a retreat. It's a strategic pivot to dominate the high-growth, large-volume drug delivery market.

Beyond the glitter, Canada's 2027 Eurovision entry is a calculated move. We analyze the steep costs, logistical hurdles, and immense economic potential.

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

Ford's new partnership with Hueler offers employees a lifetime income option, a landmark move that could redefine corporate retirement benefits across America.

Amidst digital disruption, Oconee Federal's leadership shuffle isn't just a personnel change. It's a deliberate strategy for resilience and local relevance.

A new partnership with Tandem RTM aims to solve the biggest Remote Therapeutic Monitoring adoption barriers, creating a blueprint for practice sustainability.

As commercial launches skyrocket, the FAA awards a $23M contract to ARCTOS to manage risks from debris to toxic hazards, a critical move to keep pace.

U.S. Critical Materials plants its flag in Darby, Montana, for a vital rare earth project, but its corporate charm offensive faces a wall of local resistance.

The founder of edX is betting on a faculty-built AI 'exoskeleton' to solve education's oldest problem: quality feedback at scale. Is this the future of execution?

A Vancouver firm's tech promises to turn low-grade ore into pure copper and green hydrogen, testing a new model for mining that values execution over extraction.

With its new Tensai platform, Hexaware is betting that the future of IT isn't faster fixes, but a system that intelligently removes demand altogether.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.